Collegium Pharmaceutical (COLL) Operating Leases (2019 - 2026)

Collegium Pharmaceutical's Operating Leases history runs 8 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 27.16% year-over-year to $3.8 million in Q1 2026; TTM through Mar 2026 was $3.8 million, a 27.16% decrease from a year earlier, with the FY2025 full-year figure at $4.1 million, down 39.32% from the prior year.
• Operating Leases retreated to $3.8 million in Q1 2026 per COLL's latest filing, from $4.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $7.9 million in Q1 2022 and bottomed at $3.8 million in Q1 2026.
• The 5-year median for Operating Leases is $6.1 million (2023), against an average of $6.0 million.
• Across the five-year window, Operating Leases advanced 11.2% in 2024 and plunged 39.32% in 2025, its largest moves.
• Year by year, Operating Leases stood at $7.1 million in 2022, then slipped by 13.89% to $6.1 million in 2023, then grew by 11.2% to $6.8 million in 2024, then plunged by 39.32% to $4.1 million in 2025, then declined by 8.35% to $3.8 million in 2026.
• Per Business Quant, the three latest COLL Operating Leases figures stand at $3.8 million (Q1 2026), $4.1 million (Q4 2025), and $4.5 million (Q3 2025).